0001209191-18-063896.txt : 20181221 0001209191-18-063896.hdr.sgml : 20181221 20181221161145 ACCESSION NUMBER: 0001209191-18-063896 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181206 FILED AS OF DATE: 20181221 DATE AS OF CHANGE: 20181221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HIGH SUSANNA GATTI CENTRAL INDEX KEY: 0001691005 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 181249648 MAIL ADDRESS: STREET 1: 75 LORIMER ROAD CITY: BELMONT STATE: MA ZIP: 02141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2018-12-06 2018-12-10 0 0001293971 bluebird bio, Inc. BLUE 0001691005 HIGH SUSANNA GATTI C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Operating Officer Common Stock 2018-12-06 4 M 0 15 68.65 A 15625 D Common Stock 2018-12-06 4 S 0 475 104.1333 D 15150 D Common Stock 2018-12-06 4 S 0 1100 106.1123 D 14050 D Common Stock 2018-12-06 4 S 0 300 106.7042 D 13750 D Stock Option (right to buy) 68.65 2018-12-06 4 M 0 15 0.00 D 2026-12-01 Common Stock 15 40647 D This Form 4 amendment is being filed to report the exercise of 15 stock options which was inadvertently omitted from the original Form 4 filed by the reporting person on December 10, 2018. The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. The range in prices for the transaction reported on this line was $104.01 to $104.29. The average weighted price was $104.1333. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The range in prices for the transaction reported on this line was $105.50 to $106.49. The average weighted price was $106.1123. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The range in prices for the transaction reported on this line was $106.51 to $107.42. The average weighted price was $106.7042. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. This option vests over a four-year period at a rate of twenty-five percent (25%) on November 30, 2017, and in 36 equal monthly installments thereafter. /s/ Jason F. Cole, Attorney-in-fact 2018-12-21